TESARO, Inc. is a U.S. biopharmaceutical company focused on oncology therapeutics and supportive care. Founded in 2010 and based in Waltham, Massachusetts, the company was acquired by GlaxoSmithKline (GSK) in 2019.
TESARO developed niraparib (marketed as Zejula), an oral poly(ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain ovarian cancers, and rolapitant (Varubi), a neurokinin-1 (NK1) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The company also advanced the anti-PD-1 antibody dostarlimab (now marketed by GSK as Jemperli) within its immuno-oncology pipeline.
TESARO’s programs helped expand targeted oncology options and supportive care therapies, which are now managed within GSK’s oncology portfolio.